Palantir Technologies is in hot water as MPs from various political factions demand greater oversight of the company’s involvement in the NHS. With a significant £300 million contract set to renew soon, concerns are mounting about the implications of entrusting patient data to a foreign technology firm. Palantir’s UK executive, Louis Mosley, has stepped forward to defend the company’s practices amid rising criticism.
Palantir’s Role in the NHS
Recent guidance issued to NHS trusts across England encourages the adoption of Palantir’s “core products” in hospitals, sparking backlash from multiple quarters. High-profile Labour MP Emily Darlington expressed alarm over the potential security risks posed by a “foreign tech company” handling sensitive patient data. Meanwhile, the Liberal Democrats have categorically stated that Palantir should be excluded from any role in the UK’s national security infrastructure, further amplifying the call for scrutiny.
The controversy revolves around Palantir’s Federated Data Platform (FDP), designed to integrate disparate healthcare databases that often operate in silos across different NHS facilities. This technology aims to streamline patient care by allowing healthcare providers to access vital information regarding waiting lists, available beds, and hospital supplies—all critical to improving service delivery.
Voices of Concern
Critics are voicing serious reservations about Palantir’s historical ties to the CIA and its controversial contracts with the Israeli Defence Force. Green Party leader Zack Polanski has gone so far as to label Palantir as a “military surveillance company,” raising alarms about the ethical implications of its involvement with the NHS. Conservative MP Wendy Morton has echoed these sentiments, calling for enhanced scrutiny over the company’s data protection capabilities, particularly in the wake of ongoing debates about patient trust in the NHS.
Mosley, appearing on the BBC’s Politics Live, defended Palantir’s approach, asserting that the company has no interest in accessing patient data. He stated, “It’s not our business model,” likening their role to that of Microsoft tools, which also operate without direct access to NHS data. Labour MP Alex McIntyre, a member of the Commons Health and Social Care select committee, has offered a counter-narrative, assuring that Palantir is bound by stringent regulations that ensure NHS data remains within the UK and is exclusively NHS-owned.
Political Reactions and Calls for Action
The debate has intensified as MPs from all sides weigh in on the implications of Palantir’s involvement in the NHS. Liberal Democrat leader Sir Ed Davey has called for Health Secretary Wes Streeting to terminate Palantir’s contracts with the NHS, labelling the company as “Donald Trump’s favourite tech giant” and imploring the government to consider safer, homegrown alternatives.
Critics like Darlington have raised ethical concerns, questioning whether a company whose CEO regards the NHS as a “delusion” should be trusted with one of the world’s largest repositories of patient data. She stated, “It’s a major security risk if you’re working with a company whose values do not align with those of the NHS.”
In a bid to address the backlash, Palantir’s Mosley has expressed a willingness to engage with critics and believes that the company’s record will stand up to scrutiny. He emphasises that the programme’s merit should be evaluated based on its outcomes rather than assumptions.
Government Assurance
In response to the ongoing debate, a spokesperson for the Department of Health and Social Care has reiterated that the NHS Federated Data Platform is designed to enhance patient care while ensuring strict security protocols. Each NHS Trust and Integrated Care Board maintains control over its own implementation of the platform, with specific measures in place to manage access to data.
The spokesperson highlighted the platform’s role in improving productivity and expediting cancer diagnoses, suggesting that it will ultimately benefit thousands of patients by facilitating better care coordination.
Why it Matters
The controversy surrounding Palantir’s involvement with the NHS is not just a matter of data security; it touches on broader issues of trust, ethics, and the implications of foreign influence in the UK’s healthcare system. As the NHS grapples with operational challenges, the need for innovative tech solutions must be balanced with the imperative of safeguarding sensitive patient information. The outcome of this debate will not only shape the future of NHS contracts but also set a precedent for how technology firms engage with public health services in the UK.